重组人血管内皮抑素联合放化疗治疗高级别人脑胶质瘤的临床疗效

目的探讨重组人血管内皮抑素联合放化疗治疗高级别胶质瘤的临床疗效及安全性。方法回顾性分析新乡医学院第一附属医院2012-01—2014-12收治的80例高级别人脑胶质瘤患者,其中40例采取放疗联合替莫唑胺化疗的患者为对照组,40例在对照组的基础上加用重组人血管内皮抑素治疗的患者为观察组。治疗后随访2a并进行实体肿瘤客观疗效、药物安全性的评定。结果对照组和观察组的有效率分别为45.0%和70.0%,差异有统计学意义(P0.05)。1a、2a存活率分别为50.0%、35.0%和72.5%、62.5%,差异有统计学意义(P0.05)。本组病例不良反应多为Ⅰ~Ⅱ级,无Ⅲ级以上的反应,不良反应差异无统计学意义(P0.05)。结论重组人血管内皮抑素联合放化疗治疗高级别胶质瘤能显著提高近远期临床疗效,安全性高,值得进一步临床研究。

Clinicaleffect of recombinant human endostatin combined radiotherapy and chemotherapy for high-grade gliomas

Objective To investigate the clinical efficacy and safety of recombinant human endostatin combined radiotherapy and chemotherapy for high-grade gliomas.Methods Totally 80 cases of brain glioma from January 2012 to December 2014 in the First Hospital of Xinxiang Medical College were divided into control group and observation group,40 cases in each group.The control group adopted radiotherapy combined with temozolomide chemotherapy,observation group applied recombinant human endostatin based on the control group.The patients were followed up for 2 years,and the objective curative effect and the safety of drugs were evaluated.Results The effective rate of the control group and the observation group were 45% and 70%,respectively,the difference was statistically significant (P<0.05).The one-year and two-year survival rate was 50%,35% and 72.5%,62.5%,respectively.The difference of survival rate between two groups was statistically significant (P<0.05).The adverse reactions were mostly from gradeⅠto grade Ⅱ.No grade Ⅲ or more adverse reactions were observed.There was no significant difference on adverse reactions (P>0.05).Conclusion Recombinant human endostatin combined radiotherapy and chemotherapy for high grade gliomas can significantly improve the short-and long-term clinical efficacy with a certain safety.It was worth for further clinical study.